Keyphrases
Prednisone
100%
Multiple Myeloma
100%
Maintenance Therapy
100%
Melphalan
100%
Lenalidomide Maintenance
100%
Pharmacoeconomics
100%
Cumulative Costs
80%
Survivors
40%
Lenalidomide
40%
Progression-free
40%
Cost-effectiveness
20%
Progression-free Survival
20%
Initial Treatment
20%
Phase III Clinical Trial
20%
Novel Measure
20%
Survival Events
20%
Adverse Event Data
20%
Medicine and Dentistry
Health Care Cost
100%
Maintenance Therapy
100%
Multiple Myeloma
100%
Lenalidomide
100%
Prednisone
83%
Melphalan
83%
Progression Free Survival
50%
Cost-Effectiveness Analysis
16%
Clinical Trial
16%
Adverse Event
16%
Arm
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prednisone
100%
Multiple Myeloma
100%
Melphalan
100%
Lenalidomide
100%
Pharmacoeconomics
100%
Progression Free Survival
60%
Clinical Trial
20%
Adverse Event
20%